- Corporate news
Teoxane participation at IMCAS World Congress 2023
The 2023 IMCAS congress was the opportunity for Teoxane to deep dive into its scientific expertise and holistic approach of beauty, showcasing how we constantly pioneer in the science of facial beauty.
From January 26th to 28th, Teoxane participated at the IMCAS 2023 in Paris, one of the key medical research congresses focused on providing plastic surgeons and dermatologists with the latest academic and industry updates.
IMCAS 2023 has been a major event for Teoxane, an opportunity to share its vision of beauty and its scientific expertise with all participants.
Teoxane had the chance to present a symposium entitled “Elevating Aesthetics Going beyond standards to define personal visons of beauty”. An opportunity for Teoxane’s world-renowned medical experts to share its vision of medical aesthetics with more than 800 healthcare practitioners and beauty enthusiasts. This session, the first from a brand taking part in the congress, is the third favorite session in the IMCAS 2023 report.
At the symposium, Teoxane’s international ambassadors exposed how beauty perceptions have changed over the last 20 years and supported these statements by a live full-face transformation. Also, a specific session dedicated to lips was presented to highlight Teoxane’s unique collection of products designed for lips treatment.
As part of the Global Market Summit within the congress, Teoxane’s CEO and founder Mrs. Valérie Taupin participated in a roundtable to discuss market figures and industry’ leader’s strategies in the very sector of aesthetics.
Mrs. Taupin represented Teoxane as one of the major players in the aesthetic medicine industry, underlining how hyaluronic acid-based dermal fillers are gaining momentum among overall aesthetic treatments.
Teoxane R&D Director also participated in a “Product analysis – Tear Trough Dermal filler” roundtable during which he presented Teosyal® Redensity 2 and how this product, specifically designed for the tear-trough area stands out in terms of safety and quality profile, low cases of adverse events and clinical studies.
To conclude this congress, a presentation was given about the contribution of our signature “Multilayering technique” in the treatment of the midface.
The 2023 IMCAS congress was the opportunity for Teoxane to deep dive into its scientific expertise and holistic approach of beauty, showcasing how we constantly pioneer in the science of facial beauty.